Raras
Buscar doenças, sintomas, genes...
Desmosterolose
ORPHA:35107CID-10 · Q87.8CID-11 · 5C52.10OMIM 602398DOENÇA RARA

A desmosterolose é um distúrbio muito raro da biossíntese de esterol, caracterizado por múltiplas anomalias congênitas, retardo de crescimento e deficiência intelectual, com níveis elevados de desmosterol.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A desmosterolose é um distúrbio muito raro da biossíntese de esterol, caracterizado por múltiplas anomalias congênitas, retardo de crescimento e deficiência intelectual, com níveis elevados de desmosterol.

Pesquisas ativas
1 ensaio
1 total registrados no ClinicalTrials.gov
Publicações científicas
55 artigos
Último publicado: 2026 Apr 15

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
10
pacientes catalogados
Início
Antenatal
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q87.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

😀
Face
14 sintomas
🧠
Neurológico
12 sintomas
🦴
Ossos e articulações
7 sintomas
👂
Ouvidos
5 sintomas
📏
Crescimento
5 sintomas
💪
Músculos
2 sintomas

+ 29 sintomas em outras categorias

Características mais comuns

100%prev.
Atraso global do desenvolvimento
Frequência: 9/9
100%prev.
Baixa estatura
Frequência: 4/4
100%prev.
Aplasia/Hipoplasia do corpo caloso
Frequência: 2/2
100%prev.
Anormalidade do metabolismo do colesterol
Frequência: 2/2
100%prev.
Concentração elevada de desmosterol circulante
Frequência: 10/10
100%prev.
Agenesia do corpo caloso
Muito frequente (99-80%)
84sintomas
Muito frequente (24)
Frequente (27)
Ocasional (29)
Sem dados (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 84 características clínicas mais associadas, ordenadas por frequência.

Atraso global do desenvolvimentoGlobal developmental delay
Frequência: 9/9100%
Baixa estaturaShort stature
Frequência: 4/4100%
Aplasia/Hipoplasia do corpo calosoAplasia/Hypoplasia of the corpus callosum
Frequência: 2/2100%
Anormalidade do metabolismo do colesterolAbnormality of cholesterol metabolism
Frequência: 2/2100%
Concentração elevada de desmosterol circulanteElevated circulating desmosterol concentration
Frequência: 10/10100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico55PubMed
Últimos 10 anos12publicações
Pico20233 papers
Linha do tempo
2026Hoje · 2026🧪 2021Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

DHCR24Delta(24)-sterol reductaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reduction of the delta-24 double bond of sterol intermediates during cholesterol biosynthesis (PubMed:11519011, PubMed:21671375, PubMed:22178193, PubMed:25637936). In addition to its cholesterol-synthesizing activity, can protect cells from oxidative stress by reducing caspase 3 activity during apoptosis induced by oxidative stress (PubMed:11007892, PubMed:22010141). Also protects against amyloid-beta peptide-induced apoptosis (PubMed:11007892)

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (3)
Zymostenol biosynthesis via lathosterol (Kandutsch-Russell pathway)Cholesterol biosynthesis from zymosterol (modified Kandutsch-Russell pathway)Cholesterol biosynthesis via desmosterol (Bloch pathway)
MECANISMO DE DOENÇA

Desmosterolosis

Rare autosomal recessive disorder characterized by multiple congenital anomalies and elevated levels of the cholesterol precursor desmosterol in plasma, tissue, and cultured cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
1544.2 TPM
Brain Spinal cord cervical c-1
624.1 TPM
Esôfago - Mucosa
469.7 TPM
Fígado
419.5 TPM
Skin Not Sun Exposed Suprapubic
412.1 TPM
OUTRAS DOENÇAS (1)
desmosterolosis
HGNC:2859UniProt:Q15392

Variantes genéticas (ClinVar)

31 variantes patogênicas registradas no ClinVar.

🧬 DHCR24: NM_014762.4(DHCR24):c.102C>A (p.Phe34Leu) ()
🧬 DHCR24: GRCh37/hg19 1p34.1-22.2(chr1:44475302-89585894)x3 ()
🧬 DHCR24: NM_014762.4(DHCR24):c.1055G>A (p.Arg352His) ()
🧬 DHCR24: GRCh37/hg19 1p33-32.2(chr1:47493178-57042671)x3 ()
🧬 DHCR24: Single allele ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 108 variantes classificadas pelo ClinVar.

22
70
16
Patogênica (20.4%)
VUS (64.8%)
Benigna (14.8%)
VARIANTES MAIS SIGNIFICATIVAS
DHCR24: NM_014762.4(DHCR24):c.1055G>A (p.Arg352His) [Conflicting classifications of pathogenicity]
DHCR24: NM_014762.4(DHCR24):c.1460G>A (p.Gly487Asp) [Conflicting classifications of pathogenicity]
DHCR24: NM_014762.4(DHCR24):c.958G>T (p.Glu320Ter) [Likely pathogenic]
DHCR24: NM_014762.4(DHCR24):c.1329G>A (p.Pro443=) [Conflicting classifications of pathogenicity]
DHCR24: NM_014762.4(DHCR24):c.1143C>A (p.His381Gln) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Desmosterolose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
13 papers (10 anos)
#1

DHCR24-related desmosterolosis in the first reported Turkish patient: Expanding the genotypic and phenotypic spectrum.

Journal of clinical lipidology2026 Feb

Desmosterolosis is a ultra-rare autosomal recessive disorder caused by biallelic variants in the DHCR24 gene, which encodes 3-beta-hydroxysterol delta-24-reductase-an enzyme involved in the final step of cholesterol biosynthesis. Here, we report a 3.5-year-old female with previously unreported compound heterozygous DHCR24 variants: c.1412A>G (p.Tyr471Cys), and c.275C>T (p.Thr92Met). The patient presented with agenesis of the corpus callosum, hypotonia, developmental delay, and dysmorphic facial features. Trio-clinical exome sequencing confirmed the trans configuration of the variants. Plasma desmosterol levels were elevated >50-fold (134 ng/L; reference ≤2.5 ng/L), supporting the diagnosis. In silico 3D protein modeling demonstrated structural alterations associated with both variants. A review of reported cases revealed consistent findings of corpus callosum agenesis, developmental delay, and ocular abnormalities. Our case contributes to the limited body of literature on DHCR24-related desmosterolosis and expands the variant spectrum, emphasizing the importance of integrating clinical, biochemical, and computational approaches in diagnosing rare metabolic disorders.

#2

A sterol panel for rare lipid disorders: sitosterolemia, cerebrotendinous xanthomatosis and Smith-Lemli-Opitz syndrome.

Journal of lipid research2025 Jan

Disease-specific sterols accumulate in the blood of patients with several rare lipid disorders. Biochemical measurement of these sterols is important for correct diagnosis and sometimes monitoring of treatment. Existing methods to measure sterols in blood, particularly plant sterols, are often laborious and time consuming. Partly as a result, clinical access to sterol measurements is limited in many parts of the world. A simple and rapid method to extract free sterols from human serum and quantitate their concentration using isotope-dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) without derivatization was developed. The method was designed to be compatible with routine workflows (e.g., 96-well format) in a clinical lab and extensively validated. Serum from at least 125 controls were analyzed and used to estimate the upper reference limits for sitosterol, campesterol, stigmasterol, desmosterol, 7-dehydrocholesterol (7DHC), lathosterol, and cholestanol. Serum from patients with the rare lipid disorders sitosterolemia (n = 7), Smith-Lemli-Opitz syndrome (SLOS; n = 1), and cerebrotendinous xanthomatosis (CTX; n = 1) were analyzed. All seven sitosterolemia patients had greatly elevated levels of free plant sterols (sitosterol, campesterol, and stigmasterol) compared to the controls. The SLOS serum contained massively increased concentrations of 7DHC. CTX serum contained greatly increased concentrations of cholestanol, as well as 7DHC and lathosterol. Spiking experiments indicated that the method is likely also useful for the diagnosis of desmosterolosis and lathosterolosis. The reported method is a relatively simple and fast LC-MS/MS method capable of quantitating diagnostically important sterols and differentiated patients with three rare lipid disorders from controls.

#3

Supplementation of diet with Astaxanthin and DHA prevents gestational and lactational undernourishment-induced metabolic derangements in dams: a metabolomic approach.

Journal of developmental origins of health and disease2024 Nov 28

Nutrition is the critical nongenetic factor that has a major influence on the health status of an organism. The nutritional status of the mother during gestation and lactation plays a vital role in defining the offspring's health. Undernutrition during these critical periods may induce chronic metabolic disorders like obesity and cardiovascular diseases in mothers as well as in offspring. The present study aims to evaluate the impact of undernutrition during gestational and lactational periods on the plasma metabolic profile of dams. Additionally, we investigated the potential synergistic mitigating effects of astaxanthin and docosahexaenoic acid (DHA) on dysregulated plasma metabolic profiles. Evaluation of plasma lipid profile revealed that undernourishment resulted in elevated levels of total cholesterol, triglycerides, low density and very low-density lipoproteins in dams. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) based untargeted metabolomics illustrated that pathways related to lipid metabolism, such as cholesterol metabolism, steroid biosynthesis and metabolism of amine-derived hormones, were dysregulated by undernourishment. Additionally, pathway enrichment analysis predicted that there is a high incidence of development of desmosterolosis, hypercholesterolaemia, lysosomal acid lipase deficiency and Smith-Lemli-Opitz syndrome in the offspring, reflecting predisposition in mothers. However, synergistic supplementation of astaxanthin and DHA ameliorated these adverse effects by regulating a separate set of metabolic pathways associated with lipid metabolism. They included branched chain amino acid degradation such as valine, leucine and isoleucine, metabolism of alpha-linolenic acid, lipoic acid, lysine degradation, biosynthesis, elongation and degradation of fatty acids.

#4

Exploiting in silico structural analysis to introduce emerging genotype-phenotype correlations in DHCR24-related sterol biosynthesis disorder: a case study.

Frontiers in genetics2023

Desmosterolosis is a rare sterol biosynthesis disorder characterized by multiple congenital anomalies, failure to thrive, severe developmental delay, progressive epileptic encephalopathy, and elevated levels of desmosterol caused by biallelic mutations of DHCR24 encoding 3-β-hydroxysterol Δ-24-reductase. DHCR24 is regarded as the key enzyme of cholesterol synthesis in the metabolism of brain cholesterol as it catalyzes the reduction of the Δ-24 double bond of sterol intermediates during cholesterol biosynthesis. To date, 15 DHCR24 variants, detected in 2 related and 14 unrelated patients, have been associated with the desmosterolosis disorder. Here, we describe a proband harboring the never-described DHCR24 homozygous missense variant NM_014762.4:c.506T>C, NP_055577.1:p.M169T, whose functional validation was confirmed through biochemical assay. By using molecular dynamics simulation techniques, we investigated the impact of this variant on the protein stability and interaction network with the flavin adenine dinucleotide cofactor, thereby providing a preliminary assessment of its mechanistic role in comparison to all known pathogenic variants, the wild-type protein, and a known benign DHCR24 variant. This report expands the clinical and molecular spectra of the DHCR24-related disorder, reports on a novel DHCR24 deleterious variant associated with desmosterolosis, and gives new insights into genotype-phenotype correlations.

#5

Prenatal diagnosis of lanosterol synthase deficiency: Fetal ultrasound findings as a window on family genetics.

European journal of medical genetics2023 Oct

Cholesterol is essential in the brain from the earliest stages of embryonic development. Disruption of cholesterol synthesis pathways that leads to cholesterol deficiency underlies a few syndromes, including desmosterolosis and Smith-Lemli-Opitz syndrome. In both syndromes, brain anomalies can occur. The LSS gene encodes lanosterol synthase (LSS), an important enzyme in the cholesterol biosynthesis pathway. Biallelic pathogenic variants in this gene cause alopecia-intellectual disability type 4 syndrome (APMR4, MIM 618840), a rare autosomal recessive disorder. Here, we describe two new LSS variants (c.1016C > T; p. Ser339Leu and c.1522G > C; p. Gly508Arg) found in a compound heterozygous fetus diagnosed prenatally with brain abnormalities by ultrasound scanning. Two of his siblings from the same parents also harbored these variants. Both siblings had alopecia, mild intellectual disability, autism spectrum disorder, and cataracts. To the best of our knowledge, this case represents the first prenatal diagnosis of APMR4 first suspected by ultrasound. In addition, the phenotypic features of the siblings are extensive compared with those described in previous reports and include abnormal corpus callosum, cataracts, alopecia, and developmental delay.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC14 artigos no totalmostrando 12

2026

DHCR24-related desmosterolosis in the first reported Turkish patient: Expanding the genotypic and phenotypic spectrum.

Journal of clinical lipidology
2024

Supplementation of diet with Astaxanthin and DHA prevents gestational and lactational undernourishment-induced metabolic derangements in dams: a metabolomic approach.

Journal of developmental origins of health and disease
2025

A sterol panel for rare lipid disorders: sitosterolemia, cerebrotendinous xanthomatosis and Smith-Lemli-Opitz syndrome.

Journal of lipid research
2023

Exploiting in silico structural analysis to introduce emerging genotype-phenotype correlations in DHCR24-related sterol biosynthesis disorder: a case study.

Frontiers in genetics
2023

Prenatal diagnosis of lanosterol synthase deficiency: Fetal ultrasound findings as a window on family genetics.

European journal of medical genetics
2023

First case of desmosterolosis diagnosed by prenatal whole exome sequencing.

American journal of medical genetics. Part A
2021

Generation and validation of a conditional knockout mouse model for desmosterolosis.

Journal of lipid research
2019

Desmosterolosis and desmosterol homeostasis in the developing mouse brain.

Journal of inherited metabolic disease
2019

Subcellular localization of sterol biosynthesis enzymes.

Journal of molecular histology
2018

Desmosterolosis presenting with multiple congenital anomalies.

European journal of medical genetics
2017

Measuring Activity of Cholesterol Synthesis Enzymes Using Gas Chromatography/Mass Spectrometry.

Methods in molecular biology (Clifton, N.J.)
2015

Radiographic features of the skeleton in disorders of post-squalene cholesterol biosynthesis.

Pediatric radiology
Ver todos os 14 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Desmosterolose.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Desmosterolose

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. DHCR24-related desmosterolosis in the first reported Turkish patient: Expanding the genotypic and phenotypic spectrum.
    Journal of clinical lipidology· 2026· PMID 41500862mais citado
  2. A sterol panel for rare lipid disorders: sitosterolemia, cerebrotendinous xanthomatosis and Smith-Lemli-Opitz syndrome.
    Journal of lipid research· 2025· PMID 39566847mais citado
  3. Supplementation of diet with Astaxanthin and DHA prevents gestational and lactational undernourishment-induced metabolic derangements in dams: a metabolomic approach.
    Journal of developmental origins of health and disease· 2024· PMID 39606856mais citado
  4. Exploiting in silico structural analysis to introduce emerging genotype-phenotype correlations in DHCR24-related sterol biosynthesis disorder: a case study.
    Frontiers in genetics· 2023· PMID 38239854mais citado
  5. Prenatal diagnosis of lanosterol synthase deficiency: Fetal ultrasound findings as a window on family genetics.
    European journal of medical genetics· 2023· PMID 37659595mais citado
  6. DHCR24 in cholesterol metabolism and diseases of the nervous system.
    Lipids Health Dis· 2026· PMID 41987278recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:35107(Orphanet)
  2. OMIM OMIM:602398(OMIM)
  3. MONDO:0011217(MONDO)
  4. GARD:10283(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q5264836(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Desmosterolose
Compêndio · Raras BR

Desmosterolose

ORPHA:35107 · MONDO:0011217
Prevalência
<1 / 1 000 000
Casos
10 casos conhecidos
Herança
Autosomal recessive
CID-10
Q87.8 · Outras síndromes com malformações congênitas especificadas, não classificadas em outra parte
CID-11
Ensaios
1 ativos
Início
Antenatal, Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1865596
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades